- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04889274
건강한 남성과 여성(DiNOVasc-COVID-19)의 COVID-19 백신 유도 혈관 기능 장애에 대한 식이 질산염과 섹스의 효과 조사
건강한 남성과 여성의 COVID-19 백신 유도 혈관 기능 장애에 대한 식이 질산염과 성별의 영향을 조사하기 위한 이중 맹검, 무작위, 위약 대조 병렬 연구
Inorganic nitrate can protect blood vessels from the damage that occurs during cardiovascular disease. Early experimental work suggests that nitrate-induced improvements in vascular function relate to the suppression of inflammatory pathways. Whether this protection against inflammation-induced damage to the blood vessel wall might also be functional in the setting of COVID-19 vaccination will be investigated.
Vascular function will be assessed before and after the healthy participant has received their COVID-19-vaccination. Whether there might be differences in the response to the vaccine between the sexes and whether a dietary nitrate intervention impacts upon the effects of vaccination will be investigated.
The study is in two parts:
Part A: To assess sex differences in the vascular response to COVID-19 vaccination.
Part B: To assess whether inorganic nitrate, in the form of dietary inorganic nitrate supplementation compared to placebo control, can raise circulating plasma nitrite levels and thereby prevent the systemic inflammation that causes vascular dysfunction.
연구 개요
상태
상세 설명
Whether the COVID-19 vaccine can be used to study endothelial dysfunction and whether inorganic nitrate might be useful in restoring the function of the endothelium in a scenario simulating the COVID-19 infection setting will be investigated.
Furthermore, sex differences in the vascular response to the COVID-19 vaccination will be investigated.
Design: A prospective randomised, double-blind, placebo-controlled trial.
Target population: A total of 98 healthy participants will be recruited. Part A: 30 participants (15 male, 15 female.) Part B: 68 participants (34 intervention, 34 placebo). Participants will be recruited prior to receiving the COVID-19 vaccination, via Barts Health NHS Trust approved vaccination hubs.
Setting: Equal numbers of healthy male and female volunteers, aged between 18 and 60 years of age, will be recruited. Following recruitment, participants will undergo baseline measurements of vascular function of flow mediated dilatation (FMD) and pulse wave analysis/velocity (PWA, PWV), in addition to haematological and clinical biochemical analyses. Volunteers will then be randomised into one of the 2 study Parts (Part A: sex differences in vascular response to COVID-19 vaccine, Part B: influence of dietary nitrate upon vascular responses to COVID-19 vaccine). If randomised to Part B, volunteers will be treated with 3 days of either 4-5mmol nitrate-containing beetroot juice or placebo. If randomised to Part A, the volunteers will not receive an intervention. On day 3, all participants will receive their COVID-19 vaccine. At 8±2hours after the vaccine, the participants will undergo repeat measurements of vascular function. A quality of life questionnaire will be obtained 28 days after the vaccine has been administered.
Intervention: All volunteers will receive COVID-19 vaccination in Part A and Part B. In Part B of the study, volunteers will be randomised in a 1:1 fashion to receive either nitrate-containing beetroot juice (4-5mmol nitrate) or nitrate-deplete placebo.
The study will take place in the Clinical Research Centre at The William Harvey Research Institute.
Analysis: For the analysis of Part A linear regression will be used to compare change in vascular dysfunction from pre- to post-vaccination between the sexes, unadjusted and adjusted for important risk factors including age, BMI and baseline vessel diameter. For Part B analysis of covariance (ANCOVA) will be used to compare change in vascular dysfunction from pre- to post-vaccination between dietary nitrate and placebo control groups adjusting for pre-vaccination level, and to compare change in plasma nitrite between dietary nitrate and placebo control groups adjusting for baseline nitrite level.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
London, 영국, EC1M 6BQ
- The William Harvey Research Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy volunteers with a booking for COVID-19 vaccination slot as per government guidelines
- Aged 18-60
- Volunteers who are willing to sign the consent form
Exclusion Criteria:
- Aged <18 or >60 years
- Healthy subjects unwilling to consent
- Pregnant, or any possibility that a subject may be pregnant
- History of any serious illnesses, including recent infections or trauma
- Subjects taking systemic medication (other than the oral contraceptive pill)
- Subjects with self-reported use of mouthwash or tongue scrapes
- Subjects with recent (2 weeks) or current antibiotic use
- Subjects with a history, or recent treatment of (within last 3 months) any oral condition (excluding caries), including gingivitis, periodontitis and halitosis
- Subjects with a history of COVID-19 vaccination
- Subjects with any history of a blood-borne infectious
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 파트 A: 건강한 남성 지원자
|
COVID-19 vaccine as offered by NHS England |
|
실험적: 파트 A: 건강한 여성 지원자
|
COVID-19 vaccine as offered by NHS England |
|
활성 비교기: Part B: Nitrate-rich beetroot juice
Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate |
COVID-19 vaccine as offered by NHS England Beetroot juice containing approximately 5mmol/l nitrate |
|
위약 비교기: Part B: Nitrate-deplete beetroot juice
Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted |
COVID-19 vaccine as offered by NHS England Beetroot juice with nitrate removed |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comparison of change in FMD from baseline between the sexes after COVID-19 vaccination
기간: Up to 28 days
|
A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between the sexes (i.e. males vs females) in Part A. |
Up to 28 days
|
|
Comparison of change in FMD from baseline after COVID-19 vaccination following inorganic nitrate versus placebo supplementation
기간: Up to 28 days
|
A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between intervention and placebo in Part B. |
Up to 28 days
|
|
Comparison of change in plasma [NO2-] following inorganic nitrate versus placebo supplementation
기간: Up to 28 days
|
Quantification of [NO2-] will be made using ozone chemiluminescence. Samples of blood, urine and saliva will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Measurement of [NO2-] will be made in all matrices at both timepoints, and a comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comparison between the sexes in the systemic inflammatory response to COVID-19 vaccination
기간: Up to 28 days
|
Comparisons of the inflammatory response will be made using a combination of clinical haematology and chemistry to assess leukocyte sub-types, and inflammatory markers such as C-reactive protein. Samples of blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
|
Comparison between nitrate and placebo with respect to inflammatory cell activation state
기간: Up to 28 days
|
Comparisons of the inflammatory cell activation state will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
|
Comparison between nitrate and placebo with respect to circulating inflammatory mediators
기간: Up to 28 days
|
Comparisons of the inflammatory mediators will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
|
Comparison between nitrate and placebo with respect to platelet function during systemic inflammation
기간: Up to 28 days
|
Comparisons of the platelet function will be made through the use of a platelet aggregometer and flow cytometry. Samples of citrate containing whole blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
|
Comparison between nitrate and placebo with respect to endothelium independent vasodilation of the brachial artery
기간: Up to 28 days
|
Comparisons of endothelium independent vascular function will be made through the use brachial artery ultrasound and sublingual glyceryl trinitrate. Vascular ultrasound will be conducted at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention. |
Up to 28 days
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D'Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest. 2017 Jan 3;127(1):169-182. doi: 10.1172/JCI89429. Epub 2016 Nov 28.
- Kapil V, Khambata RS, Jones DA, Rathod K, Primus C, Massimo G, Fukuto JM, Ahluwalia A. The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacol Rev. 2020 Jul;72(3):692-766. doi: 10.1124/pr.120.019240.
- Shabbir A, Rathod KS, Khambata RS, Ahluwalia A. Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:333-359. doi: 10.1146/annurev-pharmtox-010919-023229. Epub 2020 Oct 9.
- Shabbir A, Chhetri I, Khambata RS, Parakaw T, Lau C, Aubdool MABN, Massimo G, Dyson N, Kapil V, Godec T, Apea V, Flint J, Orkin C, Rathod KS, Ahluwalia A. A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study. Trials. 2023 Sep 16;24(1):593. doi: 10.1186/s13063-023-07616-2.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 21/SC/0154
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .